DIVISLAB2024-01-012024-03-31 DIVISLAB2024-01-012024-03-31 DIVISLAB2024-01-012024-03-31in-bse-fin:OneOperatingExpenses01Member DIVISLAB2024-01-012024-03-31in-bse-fin:FourOperatingExpenses01Member DIVISLAB2024-03-31 DIVISLAB2024-01-012024-03-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member DIVISLAB2024-01-012024-03-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member DIVISLAB2024-01-012024-03-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member DIVISLAB2024-01-012024-03-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532488 DIVISLAB NOTLISTED Divi's Laboratories Limited Equity 2023-04-01 2024-03-31 2024-05-25 2024-05-15 INR Crores Yearly 10:45:00 12:30:00 2024-05-25 2024-05-25 true Cash Flow Indirect Declaration of unmodified opinion Single segment Manufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients. 2024-01-01 2024-03-31 Audited Consolidated 23030000000.00 790000000.00 23820000000.00 8980000000.00 60000000.00 -20000000.00 2970000000.00 20000000.00 950000000.00 3730000000.00 16690000000.00 7130000000.00 0.00 7130000000.00 1600000000.00 150000000.00 1750000000.00 0.00 5380000000.00 0.00 0.00 0.00 0.00 5380000000.00 -70000000.00 5310000000.00 5380000000.00 0.00 5310000000.00 0.00 530000000.00 2 20.25 20.25 0.00 0.00 20.25 20.25 1. The above Statement of consolidated audited financial results for the quarter and year ended March 31, 2024, Consolidated audited statement of assets and liabilities and Consolidated audited statement of cash flows as at and for the year then ended March 31, 2024 ('Consolidated Statements') are prepared in accordance with Indian Accounting Standards ('lndAS') prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The same were, as reviewed by the Audit Committee, considered and approved by the Board of Directors at its meeting held on May 25, 2024. The statutory auditors have audited the consolidated statement and issued an unmodified report thereron. 2. The consolidated results include the audited financial results of the wholly owned subsidiaries Divis Laboratories (USA) Inc and Divi’s Laboratories Europe AG. 3. The Group is engaged in the manufacture of Active Pharmaceutical Ingredients, intermediates and nutraceutical ingredients; and the same constitutes a single reportable business segment as per Ind AS 108. 4. The Group does not have any discontinued operations and the Profit for the year represents the Profits from continuing operations only. 5. **Figures for the quarter ended 31.03.2024 and corresponding quarter ended 31.03.2023 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter of the respective financial years. 6. The Board of Directors of the company has recommended a dividend of Rs. 30/- per share of face value Rs. 2/- each i.e.,1,500% for the financial year 2023-24, subject to approval of members at the ensuing annual general meeting. 7. Details of forex gain/(loss) are as given below: (Rs. in Crores) Quarter ended Year Ended 31.03.2024 31.12.2023 31.03.2023 31.03.2024 31.03.2023 (Audited)** (Unaudited) (Audited)** (Audited) (Audited) Forex gain/ (loss) (2) 18 (4) 30 130 Forex gain has been included in Other Income and loss has been included in Other Expenses. Single segment 2023-04-01 2024-03-31 Audited Consolidated 78450000000.00 3390000000.00 81840000000.00 32320000000.00 60000000.00 -1090000000.00 10940000000.00 30000000.00 3780000000.00 14170000000.00 60210000000.00 21630000000.00 0.00 21630000000.00 5140000000.00 490000000.00 5630000000.00 0.00 16000000000.00 0.00 0.00 0.00 0.00 16000000000.00 0.00 16000000000.00 16000000000.00 0.00 16000000000.00 0.00 530000000.00 2 135180000000.00 60.27 60.27 0.00 0.00 60.27 60.27 Other Expenses 3730000000.00 Other Expenses 14170000000.00 47330000000.00 7780000000.00 0.00 60000000.00 820000000.00 0.00 560000000.00 1380000000.00 100000000.00 1300000000.00 57950000000.00 31840000000.00 0.00 21560000000.00 3630000000.00 36170000000.00 0.00 70000000.00 61430000000.00 3480000000.00 96750000000.00 154700000000.00 530000000.00 135180000000.00 135710000000.00 135710000000.00 0.00 20000000.00 20000000.00 370000000.00 5820000000.00 6210000000.00 0.00 8240000000.00 1010000000.00 9250000000.00 3030000000.00 70000000.00 430000000.00 12780000000.00 18990000000.00 154700000000.00 30000000.00 -1840000000.00 -3610000000.00 0.00 -1190000000.00 -70000000.00 -50000000.00 -10000000.00 0.00 620000000.00 0.00 70000000.00 0.00 3780000000.00 0.00 0.00 0.00 -30000000.00 40000000.00 -20000000.00 0.00 3010000000.00 0.00 -50000000.00 0.00 0.00 0.00 80000000.00 0.00 -5260000000.00 16370000000.00 0.00 0.00 0.00 3760000000.00 0.00 12610000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 10030000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3000000000.00 0.00 4340000000.00 0.00 -2690000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 10000000.00 7960000000.00 20000000.00 0.00 0.00 -7990000000.00 1930000000.00 0.00 1930000000.00 1700000000.00 3630000000.00 Gain/loss on Remeasurement of post-employment benefit obligations -50000000.00 Gain/loss on Remeasurement of post-employment benefit obligations -20000000.00 -50000000.00 -20000000.00 -20000000.00 -10000000.00 Gain/loss on Exchange differences in translating the financial statements of foreign operations -40000000.00 Gain/loss on Exchange differences in translating the financial statements of foreign operations 20000000.00 -40000000.00 20000000.00 0.00 10000000.00